

Rule 3.19A.2

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	G Medical Innovations Holdings Limited
<b>ARBN</b>	617 204 743

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Kenneth R Melani
<b>Date of last notice</b>	25 March 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	11 May 2020
<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"><li>5,309,438 fully paid ordinary shares</li><li>685,335 Class C Performance Rights</li></ul>
<b>Class</b>	Fully paid ordinary shares and Class C Performance Rights
<b>Number acquired</b>	3,639,013 fully paid ordinary shares
<b>Number disposed</b>	685,335 Class C Performance Rights
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Fully paid ordinary shares - non-cash, shares transferred from director, Yacov Geva to settle a loan provided to the company by Kenneth Melani valued at US\$200,000  Performance Rights - Nil, lapse of rights after conversion milestone not satisfied

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>No. of securities held after change</b>	8,948,451 fully paid ordinary shares
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	As above

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	G Medical Innovations Holdings Limited
<b>ARBN</b>	617 204 743

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Brendan de Kauwe
<b>Date of last notice</b>	27 March 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Beneficial Holder Securities registered in the name of - Attollo Investments Pty Ltd <Attollo Investment A/C>
<b>Date of change</b>	1 May and 10 May 2020
<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"><li>• 4,420,455 fully paid ordinary shares</li><li>• 681,818 Class C Performance Rights</li><li>• 2,500,000 unlisted options (\$0.30, 1 May 2020)</li></ul>
<b>Class</b>	See below
<b>Number acquired</b>	Nil
<b>Number disposed</b>	2,500,000 unlisted options (\$0.30, 1 May 2020) on expiry on 1 May 2020  681,818 Class C Performance Rights on lapse of rights after conversion milestone unsatisfied on 10 May 2020
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>No. of securities held after change</b>	4,420,455 fully paid ordinary shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of options and lapse of performance rights

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	G Medical Innovations Holdings Limited
<b>ARBN</b>	617 204 743

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Yacov Geva
<b>Date of last notice</b>	9 April 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	<div><div>1</div>Indirect</div> <div><div>2</div>Indirect</div> <div><div>3</div>Indirect</div> <div><div>4</div>Indirect</div> <div><div>5</div>Indirect</div> <div><div>6</div>Direct</div>
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<div><div>1</div>Beneficial holding held through and registered in the name of Bank Julius Baer &amp; Co Ltd</div> <div><div>2</div>Beneficial holding held through custodian and registered in the name of HSBC Custody Nominees (Australia) Limited</div> <div><div>3</div>Beneficial holding held through custodian and registered in the name of J P Morgan Nominees Australia Pty Limited</div> <div><div>4</div>Beneficial holding held through custodian and registered in the name of Millinium Capital Managers Limited</div> <div><div>5</div>Beneficial holding through custodian, Banque J Safra Sarasin</div>
<b>Date of change</b>	11 May 2020

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held prior to change</b>	1 49,745,275 Class C Performance Rights 2 3,672,000 fully paid ordinary shares 3 181,978,322 fully paid ordinary shares 4 4,990,000 fully paid ordinary shares 5 93,339,307 fully paid ordinary shares 6 10,951,000 fully paid ordinary shares
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	1. Nil 2. Nil 3. Nil 4. Nil 5. Nil 6. Nil
<b>Number disposed</b>	1. 49,745,275 Class C Performance Rights 2. Nil 3. Nil 4. Nil 5. 3,639,013 fully paid ordinary shares 6. Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	- Performance Rights – Nil, lapse of rights after conversion milestone not satisfied  - Shares - Non-cash, shares transferred to director, Kenneth Melani to settle a loan provided to the company valued at US\$200,000
<b>No. of securities held after change</b>	1 Nil 2 3,672,000 fully paid ordinary shares 3 181,978,322 fully paid ordinary shares 4 4,990,000 fully paid ordinary shares 5 89,700,294 fully paid ordinary shares 6 10,951,000 fully paid ordinary shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	As above

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.